雌激素通过FTO基因调控子宫内膜癌细胞的增殖活性

目的:探讨雌激素对子宫内膜癌细胞系ishikawa细胞中肥胖相关基因FTO表达的调控机制以及对增殖的影响。方法:RT-PCR及细胞免疫荧光法检测不同浓度雌激素处理后ishikawa细胞中FTO表达水平的变化,PCR方法检测雌激素是否通过PI3K/AKT和MAPK信号通路对FTO进行调控,应用siRNA干扰法和MTT分析法检测FTO基因对细胞增殖的影响。结果:(1)不同浓度雌激素均可上调ishkawa细胞中FTO mRNA的表达,以10-9mol/L作用最明显,与对照组的差异有统计学意义(P<0.05);(2)E2+LY294002、E2+U0126组FTO mRNA表达水平比单独加雌激素组显著降低,差异有统计学意义(P<0.05),E2+LY294002+U0126联合加通路抑制剂组比E2+LY294002、E2+U0126单独加通路抑制剂组明显降低,差异有统计学意义(P<0.05);(3)siFTO干扰组FTO mRNA表达水平比阴性对照组明显降低,干扰效率达40%(P<0.05),FTO被干扰后,细胞的增殖活性受到明显的抑制,差异有统计学意义(P<0.05)。结论:雌激素通过受PI3K/AKT和MAPK信号通路调控的FTO基因调控细胞的增殖活性。     

雌激素受体β与上皮性卵巢癌关系研究进展

雌激素受体β在人的卵巢组织中优势表达,在卵巢癌中发现雌激素受体β表达下降。雌激素受体β作为一种雌激素受体的亚型,在许多方面都起着与雌激素受体α相反的作用。雌激素受体β可抑制卵巢癌细胞增殖,呈配体非依赖性。卵巢癌常常存在染色体14q部分缺失,而雌激素受体β恰巧位于这一区域,故而在卵巢癌中表达下降。该文从雌激素受体β的结构特点、组织学分布、生理功能以及与卵巢癌的关系等方面进行简要综述。     

GSK-3β对子宫内膜样腺癌细胞增殖和侵袭的影响

目的：研究糖原合成酶激酶-3β（glycogensynthasekinase，GSK-3β）对子宫内膜样腺癌已分化细胞株Ishikawa、HEC-1-A及未分化细胞株KLE增殖和侵袭能力的影响。方法：用GSK-3β小分子干扰RNA（GSK-3β siRNA）转染上述3种细胞株，采用Western印迹法检测GSK-38蛋白及凋亡相关蛋白caspase-3的表达；Brdu掺入实验检测细胞增殖率；FCM法检测细胞周期及凋亡率；Transwell侵袭试验检测对细胞侵袭、运动能力的影响；明胶酶谱法检测细胞分泌基质金属蛋白酶-2（MMP-2）的情况。结果：转染GSK-3β siRNA后，3种细胞株中GSK-3β蛋白的表达均低于对照组（P〈0．05）；Ishikawa、HEC-1-A细胞Brdu掺入率降低，S期细胞数比例减少，凋亡率增加，caspase-3表达上调；细胞侵袭能力降低，与对照组相比差异有统计学意义（P〈0．01）。但是KLE细胞株与对照组相比，增殖和侵袭能力均无明显差异（均为P〉0．05）。结论：GSK-3β能促进已分化的子宫内膜样腺癌细胞株Ishikawa、HEC-1-A的增殖和侵袭；但是对未分化的KLE细胞株的增殖和侵袭能力无明显影响。     

盐酸拓扑替康腹腔注射对大鼠腹腔器官及外周血白细胞的影响

目的 :探索拓扑替康腹腔化疗的安全性和可行性。方法 :以健康SD雌性大鼠为研究对象 ,观察拓扑替康腹腔化疗对大鼠腹腔内器官和外周血白细胞的影响。结果 :在剂量与静脉化疗总量相同和加大一倍时 ,拓扑替康腹腔化疗除引起与对照组相同的子宫炎症反应外 ,大网膜产生炎症反应 ;对卵巢和胰腺等则均无明显影响 ;当应用 4倍剂量时 ,造成胰腺实质间质部炎症反应。对外周血白细胞计数的影响与剂量有关 ,虽然各剂量腹腔化疗后第 3天 ,外周血白细胞计数都有下降 ,但仅在相当于静脉化疗剂量 2倍时 ,下降有统计学意义 ,剂量加大至 4倍时 ,虽然无统计学意义 ,但此实验组的白细胞计数在化疗后 5天无明显回升 ,直至化疗后 8天才恢复。其他实验组白细胞计数在化疗后 5天已回升至化疗前水平。结论 :拓扑替康腹腔化疗对大鼠外周血白细胞计数无严重影响 ,在适当剂量下对腹腔各正常器官也无明显刺激 ,对其一般情况等无明显作用。所以 ,在适当剂量下拓扑替康腹腔化疗是安全的 ,它为治疗卵巢肿瘤 ,特别是晚期、复发及耐药的卵巢肿瘤提供了新的途径。     

Inhibitory effect of medroxyprogesterone acetate on malignant growth of ovarian cancer 3AO cell line

Ｉｎｈｉｂｉｔｏｒｙｅｆｆｅｃｔｏｆｍｅｄｒｏｘｙｐｒｏｇｅｓｔｅｒｏｎｅａｃｅｔａｔｅｏｎｍａｌｉｇｎａｎｔｇｒｏｗｔｈｏｆｏｖａｒｉａｎｃａｎｃｅｒ　３ＡＯｃｅｌｌｌｉｎｅＪｉｎＺｈｉｊｕｎ（金志军）；ＺｈａｎｇＸｉｙｉｎ（张惜阴）；ＦｅｎｇＹｏ...     

腹腔镜腹膜代阴道成形术与腹腔镜辅助乙状结肠代阴道成形术的对比分析

目的:探讨腹腔镜腹膜代阴道成形术与腹腔镜辅助乙状结肠代阴道成形术在先天性无阴道疾病治疗中的临床应用价值.方法:选取2003年1月～2013年12月该院收治的40例先天性无阴道患者,其中25例行腹腔镜辅助乙状结肠代阴道成形术为结肠组,15例行腹腔镜腹膜代阴道成形术为腹膜组,比较两种术式的围手术期参数及术后疗效.结果:40例患者均在腹腔镜下成功完成手术,腹膜组手术时间、术中出血量、住院时间及住院费用均优于结肠组,两组比较,差异有统计学意义(P＜0.05).术后随访发现,两组性功能指数量表(FSFI)总评分比较,差异无统计学意义(P＜0.05).结论:腹腔镜腹膜代阴道成形术和腹腔镜辅助乙状结肠代阴道成形术术后疗效相仿,但腹腔镜腹膜代阴道成形术更方便、经济、微创,值得临床推广应用.     

应用RNA干扰技术研究survivin基因对子宫内膜癌细胞增殖和细胞周期的调节作用

survivin基因是近年来发现的在大多数肿瘤组织中高表达的基因，具有调控细胞周期和细胞凋亡的双重作用，与肿瘤的发生密切相关，抑制其功能将有助于肿瘤的治疗。RNA干扰（RNA interference，RNAi）技术是利用双链RNA在转录后水平特异性地抑制基因表达的一项技术，是研究基因功能和基因治疗的有力工具。本研究应用RNAi技术，将自行设计和构建包含有针对survivin基因的特异性小分子干扰RNA（siRNA）的重组质粒转染入子宫内膜癌细胞，以观察阻断survivin基因表达对细胞增殖和细胞周期的影响。     

上海市浦东新区妇女绝经年龄及行经年限调查与影响因素分析

Objective To investigate natural spontaneous menopausal age , menstruation span and their relationship with menarche age and parity in Pudong district of Shanghai. Methods From Jan 2007 to Jul 2008, 15 083 spontaneous menopause women undergoing cervical cancer screening were enrolled in this study. The questionnaire included menarche age, parity, spontaneous menopausal age and menstruation span. Those women were divided into four groups based on age, which were group of 56 -60, 61 -65, 66 -70 and more than 70. Analysis of variance (ANOVA) was used for comparing difference between menopausal age and menstruation span. Multiple factor regressions was used to analyze the relationship between menarche age, parity and menopausal age and menstruation span. Results (1) Spontaneous menopausal age: the minimum was 29 years old, the maximum was 61 years old, and the mean age was (50.6 ±3.7)years old. The mean spontaneous menopause age were (50.9 ± 3.4), ( 50.7 ± 3.7 ), (50.0 ± 4.1 ), (49.6 ±4.0) years in groups of 56 -60, 61 -65, 66 -70 and more than 70 years. With the increasing age range in four groups, the increasing trends of menopausal age were observed, which the difference of 1.36 year was shown between groups of 56 - 60 and more than 70 years. (2) Menstruation span: the mean of menstruation span was (34.3 ± 4.1 ) years, which the minimal age of 12 years and maximal age of 48 years were recorded. (34.6 ± 3.8), (34.3 ± 4.1 ), (33.9 ± 4.6), (33.2 ± 4. 5) were observed in groups of 56 - 60,61 -65, 66 -70 and more than 70 years. With the increasing age range in four groups, the increasing trends of menstruation span were observed, which the difference of 1.41 year was shown between groups of 56 –60 and more than 70 years. (3)The impact of menarche age on menopausal age and menstruation span: there was no correlation between menarche age and menopausal age ( r = 0.02); however, menstruation span was found to be negatively correlated with the menarche age ( r = - 0.43 ). (4) The impact of parity on menopausal age and menstruation span: the mean menopausal age of women who had 1 -2 deliveries was significantly higher than those had no delivery or more than 3 deliveries ( P < 0.05 ). However, there was no difference in menopausal age between women with 1 and 2 deliveries or between women without delivery and more than 3 deliveries (P > 0.05). Menstruation span of women with 1 delivery was significantly longer that those with more than 1 delivery( P < 0.05 ), similarly, women with 2 deliveries had longer menstruation span than women without delivery or more than 3 deliveries(P < 0.05 ). There were no difference in menstruation span between women with more than 3 deliveries and without delivery ( P >0.05 ). (5) Multifactor regression analysis for menstruation span: menarche age was correlated with menstruation span negatively ( r = - 0.97,P <0.001 ). There was significantly different menstruation span between group of 61 -65, 66 -70 or more than 70 years and group of 56-60 (r= -0. 18, P=0.020; r= -0.78,P <0.001 and r= - 1.23,P<0.001). Menstruation span in women with 1 -2 deliveries was significantly longer than that of women without delivery or more than 3 deliveries. (6)Multifactor logistic analysis of menopausal age: there was no association between menarche age and menopausal age, however, significant differences were found in mean menopausal age between different groups, which show that menopausal age of group 56 - 60 years was significant higher than the other groups, including age-group 61 -65 years ,66 -70 years and over 70 years ( r = - 0.18, P = 0.020; r = - 0.78,P < 0.001; r = - 1.23, P < 0.001 ). Menopausal age in women with 1 - 2 deliveries was significantly higher than those of women without delivery or with more than 3 deliveries,however, no difference between women with 1 and 2 deliveries or between women without deliveries and more than 3 deliveries was observed. Conclusion (1) Menopausal age and menstruation span exhibited increasing trends in Pudong district of Shanghai. (2) Menarche age and parity were the important factors influencing menopausal age and menstruation span. (3) With younger age of menarche, the menstruation span become longer. (4) Deliveries of 1 -2 times can significantly delay the menopause and prolong menstruation span, however, the multiple deliveries ( ≥ 3 times) had no significant impact on menopausal age and menstruation span.     

重视妇科肿瘤的规范诊治

“无论何时，无论何地，无论何人，无论怎样强调重视医疗规范诊治，都不为过!”在当前医疗实践中，重视、遵循《医疗规范诊治》，至少有两大作用。[第一段]     

TNF相关凋亡诱导配体在卵巢癌基因治疗中的应用

肿瘤坏死因子相关凋亡诱导配体(TRAIL)是新近发现的肿瘤坏死因子(TNF)超家族成员，有2类受体，一类是死亡受体，能诱导多种肿瘤细胞凋亡；另一类是诱骗受体，没有胞内死亡区域，不传递凋亡信号。TRAIL有广谱的抗瘤作用，与传统的放疗，化疗有协同作用，且对正常组织细胞无毒性，因此有望应用于肿瘤基因治疗。可通过补充细胞因子或通过基因补充，为癌症治疗提供一个新的有希望的治疗方法。